Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
-
Immunotherapy combo shows promise in ovarian cancer before surgery
Disease control CompletedThis study tested whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy before surgery is safe and feasible for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. 69 participants were randomly assigned to different …
Phase: PHASE1, PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 17, 2026 04:40 UTC
-
Immunotherapy combo shows promise in Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with advanced ovarian cancer. About 91 participants received either chemo alone or chemo plus pembrolizumab. The goal was to see if the combination…
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
When is the best time for ovarian cancer surgery? new trial investigates
Disease control CompletedThis study looked at 211 women with advanced ovarian cancer who were not candidates for immediate surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing led to longer periods without the cancer coming ba…
Phase: NA • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Ovarian cancer genetics under the microscope: no treatment, just knowledge
Knowledge-focused CompletedThis study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC